# Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

> **NCT00387270** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medivation, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** Dimebon

## Key facts

- **NCT ID:** NCT00387270
- **Lead sponsor:** Medivation, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2008-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387270, "Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00387270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*